DiagnoCure Inc. Reports Financial and Operational Results for the Fourth Quarter and Fiscal Year Ended October 31, 2012; Reports Impairment of Intangible Assets for the Fourth Quarter of 2012
January 12, 2013 at 03:13 am IST
Share
DiagnoCure Inc. reported financial and operational results for the fourth quarter 2012 and fiscal year ended October 31, 2012. For the quarter, the company reported total revenues of CAD 142,995 against CAD 345,923 a year ago. Net loss from continuing operations (before stock-based compensation and amortization) CAD 1,048,993 against CAD 329,980 a year ago. Net loss from continuing operations was CAD 1,978,355 or CAD 0.05 basic and diluted per share against CAD 2,294,559 or CAD 0.06 basic and diluted per share a year ago.
For the year, the company reported total revenues of CAD 2,472,038 against CAD 1,241,781 a year ago. Net loss from continuing operations (before stock-based compensation and amortization) CAD 1,884,056 against CAD 2,095,867 a year ago. Net loss from continuing operations was CAD 3,679,324 or CAD 0.09 basic and diluted per share against CAD 5,257,438 or CAD 0.12 basic and diluted per share a year ago.
The company reported Impairment of intangible asset for the fourth quarter was CAD 650,000 compared to CAD 713,046,000 a year ago.
9342-8530 Quebec Inc is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling, or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).
DiagnoCure Inc. Reports Financial and Operational Results for the Fourth Quarter and Fiscal Year Ended October 31, 2012; Reports Impairment of Intangible Assets for the Fourth Quarter of 2012
9342-8530 QUÉBEC INC. 
